130 related articles for article (PubMed ID: 31667887)
1. Identification of the best-suited donor for generating virus-specific T cells.
Tasnády S; Karászi É; Szederjesi A; Bihari G; Juhász Z; Hardi A; Kriván G; Kállay K; Reményi P; Sinkó J; Mikala G; Réti M; Masszi T
Vox Sang; 2020 Jan; 115(1):18-26. PubMed ID: 31667887
[TBL] [Abstract][Full Text] [Related]
2. Third-Party and Patient-Specific Donor-Derived Virus-Specific T Cells Demonstrate Similar Efficacy and Safety for Management of Viral Infections after Hematopoietic Stem Cell Transplantation in Children and Young Adults.
Galletta TJ; Lane A; Lutzko C; Leemhuis T; Cancelas JA; Khoury R; Wang YM; Hanley PJ; Keller MD; Bollard CM; Davies SM; Grimley MS; Rubinstein JD
Transplant Cell Ther; 2023 May; 29(5):305-310. PubMed ID: 36736781
[TBL] [Abstract][Full Text] [Related]
3. Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial.
Qian C; Campidelli A; Wang Y; Cai H; Venard V; Jeulin H; Dalle JH; Pochon C; D'aveni M; Bruno B; Paillard C; Vigouroux S; Jubert C; Ceballos P; Marie-Cardine A; Galambrun C; Cholle C; Clerc Urmes I; Petitpain N; De Carvalho Bittencourt M; Decot V; Reppel L; Salmon A; Clement L; Bensoussan D
J Hematol Oncol; 2017 May; 10(1):102. PubMed ID: 28482908
[TBL] [Abstract][Full Text] [Related]
4. High-intensity interval training in allogeneic adoptive T-cell immunotherapy - a big HIT?
Heinemann NC; Tischer-Zimmermann S; Wittke TC; Eigendorf J; Kerling A; Framke T; Melk A; Heuft HG; Blasczyk R; Maecker-Kolhoff B; Eiz-Vesper B
J Transl Med; 2020 Apr; 18(1):148. PubMed ID: 32238166
[TBL] [Abstract][Full Text] [Related]
5. Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes.
Naik S; Nicholas SK; Martinez CA; Leen AM; Hanley PJ; Gottschalk SM; Rooney CM; Hanson IC; Krance RA; Shpall EJ; Cruz CR; Amrolia P; Lucchini G; Bunin N; Heimall J; Klein OR; Gennery AR; Slatter MA; Vickers MA; Orange JS; Heslop HE; Bollard CM; Keller MD
J Allergy Clin Immunol; 2016 May; 137(5):1498-1505.e1. PubMed ID: 26920464
[TBL] [Abstract][Full Text] [Related]
6. The effects of β
Kunz HE; Agha NH; Hussain M; LaVoy EC; Smith KA; Mylabathula P; Diak D; Baker FL; O'Connor DP; Bond RA; Katsanis E; Bollard CM; Simpson RJ
Cell Stress Chaperones; 2020 Nov; 25(6):993-1012. PubMed ID: 32779001
[TBL] [Abstract][Full Text] [Related]
7. Establishment and Operation of a Third-Party Virus-Specific T Cell Bank within an Allogeneic Stem Cell Transplant Program.
Withers B; Clancy L; Burgess J; Simms R; Brown R; Micklethwaite K; Blyth E; Gottlieb D
Biol Blood Marrow Transplant; 2018 Dec; 24(12):2433-2442. PubMed ID: 30172015
[TBL] [Abstract][Full Text] [Related]
8. Rapid generation of clinical-grade antiviral T cells: selection of suitable T-cell donors and GMP-compliant manufacturing of antiviral T cells.
Tischer S; Priesner C; Heuft HG; Goudeva L; Mende W; Barthold M; Kloeß S; Arseniev L; Aleksandrova K; Maecker-Kolhoff B; Blasczyk R; Koehl U; Eiz-Vesper B
J Transl Med; 2014 Dec; 12():336. PubMed ID: 25510656
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus-specific T-lymphocyte efficacy in the presence of methylprednisolone: An in vitro study.
Campidelli A; Qian C; Laroye C; Decot V; Reppel L; D'aveni M; Bensoussan D
Cytotherapy; 2018 Apr; 20(4):524-531. PubMed ID: 29496461
[TBL] [Abstract][Full Text] [Related]
10. [Immunotherapy for refractory viral infections].
Morio T; Fujita Y; Takahashi S
Rinsho Ketsueki; 2018; 59(2):205-215. PubMed ID: 29515076
[TBL] [Abstract][Full Text] [Related]
11. CD123 redirected multiple virus-specific T cells for acute myeloid leukemia.
Zhou L; Liu X; Wang X; Sun Z; Song XT
Leuk Res; 2016 Feb; 41():76-84. PubMed ID: 26740053
[TBL] [Abstract][Full Text] [Related]
12. Banking on virus-specific T cells to fulfill the need for off-the-shelf cell therapies.
Quach DH; Lulla P; Rooney CM
Blood; 2023 Feb; 141(8):877-885. PubMed ID: 36574622
[TBL] [Abstract][Full Text] [Related]
13. Virus-Specific T Cells: Current and Future Use in Primary Immunodeficiency Disorders.
Harris KM; Davila BJ; Bollard CM; Keller MD
J Allergy Clin Immunol Pract; 2019 Mar; 7(3):809-818. PubMed ID: 30581131
[TBL] [Abstract][Full Text] [Related]
14. T-cell receptor sequencing demonstrates persistence of virus-specific T cells after antiviral immunotherapy.
Keller MD; Darko S; Lang H; Ransier A; Lazarski CA; Wang Y; Hanley PJ; Davila BJ; Heimall JR; Ambinder RF; Barrett AJ; Rooney CM; Heslop HE; Douek DC; Bollard CM
Br J Haematol; 2019 Oct; 187(2):206-218. PubMed ID: 31219185
[TBL] [Abstract][Full Text] [Related]
15. Manufacturing of highly functional and specific T cells for adoptive immunotherapy against virus from granulocyte colony-stimulating factor-mobilized donors.
Beloki L; Ramírez N; Olavarría E; Samuel ER; Lowdell MW
Cytotherapy; 2014 Oct; 16(10):1390-408. PubMed ID: 24954783
[TBL] [Abstract][Full Text] [Related]
16. Simple and efficient generation of virus-specific T cells for adoptive therapy using anti-4-1BB antibody.
Imahashi N; Nishida T; Goto T; Terakura S; Watanabe K; Hanajiri R; Sakemura R; Imai M; Kiyoi H; Naoe T; Murata M
J Immunother; 2015; 38(2):62-70. PubMed ID: 25658615
[TBL] [Abstract][Full Text] [Related]
17. Transgenic CD8αβ co-receptor rescues endogenous TCR function in TCR-transgenic virus-specific T cells.
Bajwa G; Lanz I; Cardenas M; Brenner MK; Arber C
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33148692
[TBL] [Abstract][Full Text] [Related]
18. Early Experience With CliniMACS Prodigy CCS (IFN-gamma) System in Selection of Virus-specific T Cells From Third-party Donors for Pediatric Patients With Severe Viral Infections After Hematopoietic Stem Cell Transplantation.
Kállay K; Kassa C; Réti M; Karászi É; Sinkó J; Goda V; Stréhn A; Csordás K; Horváth O; Szederjesi A; Tasnády S; Hardi A; Kriván G
J Immunother; 2018 Apr; 41(3):158-163. PubMed ID: 29239916
[TBL] [Abstract][Full Text] [Related]
19. A single exercise bout enhances the manufacture of viral-specific T-cells from healthy donors: implications for allogeneic adoptive transfer immunotherapy.
Spielmann G; Bollard CM; Kunz H; Hanley PJ; Simpson RJ
Sci Rep; 2016 May; 6():25852. PubMed ID: 27181409
[TBL] [Abstract][Full Text] [Related]
20. A cost-effective strategy for selection of third-party donors for a virus-specific T-cell bank for an Asian patient population.
Linn YC; Sundar Raj K; Teo B; Phang CY; Chittezhath M; Koh M
Cytotherapy; 2023 May; 25(5):510-520. PubMed ID: 36882347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
